Climb Bio Inc (NASDAQ:CLYM) shares, rose in value on Wednesday, June 18, with the stock price up by 2.50% to the previous day’s close as strong demand from buyers drove the stock to $1.23.
Actively observing the price movement in the last trading, the stock closed the session at $1.20, falling within a range of $1.16 and $1.2899. The value of beta (5-year monthly) was -0.157. Referring to stock’s 52-week performance, its high was $9.21, and the low was $1.05. On the whole, CLYM has fluctuated by -3.15% over the past month.
With the market capitalization of Climb Bio Inc currently standing at about $83.12 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CLYM’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CLYM currently trading nearly -1.64% and -1.56% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.64, while the 7-day volatility ratio is showing 3.53% which for the 30-day chart, stands at 4.75%. Furthermore, Climb Bio Inc (CLYM)’s beta value is -0.15, and its average true range (ATR) is 0.10.
A comparison of Climb Bio Inc (CLYM) with its peers suggests the former has fared considerably weaker in the market. CLYM showed an intraday change of 2.50% in last session, and over the past year, it shrunk by -86.04%%.
Data on historical trading for Climb Bio Inc (NASDAQ:CLYM) indicates that the trading volumes over the past 10 days have averaged 0.26 and over the past 3 months, they’ve averaged 161.97K. According to company’s latest data on outstanding shares, there are 67.58 million shares outstanding.
Nearly 13.88% of Climb Bio Inc’s shares belong to company insiders and institutional investors own 76.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.19 million shares as on 2025-05-30, resulting in a short ratio of 15.23. According to the data, the short interest in Climb Bio Inc (CLYM) stood at 608.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 2.32 million. The stock has fallen by -31.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CLYM stock heading into the next quarter.
